<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Source Themes Academic 4.6.3"><meta name=author content="Raphael Scheible"><meta name=description content="Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1 to 25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients had (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0 - 88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, only severe combined immunodeficiency (SCID) had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49 % of all patients received immunoglobulin G (IgG) substitution (70% - subcutaneous; 29% - intravenous; 1% - unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment."><link rel=alternate hreflang=en-us href=https://raphiniert.com/publication/el-helou-german-2019/><meta name=theme-color content=#d9230f><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.11.2/css/all.min.css integrity="sha256-+N4/V/SbAFiW1MPBCXnfnP9QSN3+Keu+NlB+0ev/YKQ=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/github.min.css crossorigin=anonymous title=hl-light><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/dracula.min.css crossorigin=anonymous title=hl-dark disabled><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin=anonymous><script src=https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin=anonymous async></script><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap"><link rel=stylesheet href=/css/academic.css><link rel=manifest href=/index.webmanifest><link rel=icon type=image/png href=/img/icon-32.png><link rel=apple-touch-icon type=image/png href=/img/icon-192.png><link rel=canonical href=https://raphiniert.com/publication/el-helou-german-2019/><meta property=twitter:card content=summary><meta property=og:site_name content="Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"><meta property=og:url content=https://raphiniert.com/publication/el-helou-german-2019/><meta property=og:title content="The German National Registry of Primary Immunodeficiencies (2012–2017) | Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"><meta property=og:description content="Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1 to 25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients had (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0 - 88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, only severe combined immunodeficiency (SCID) had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49 % of all patients received immunoglobulin G (IgG) substitution (70% - subcutaneous; 29% - intravenous; 1% - unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment."><meta property=og:image content=https://raphiniert.com/img/raphiniert.png><meta property=twitter:image content=https://raphiniert.com/img/raphiniert.png><meta property=og:locale content=en-us><meta property=article:published_time content=2020-12-08T15:33:48&#43;00:00><meta property=article:modified_time content=2020-12-08T16:21:51&#43;01:00><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://raphiniert.com/publication/el-helou-german-2019/"},"headline":"The German National Registry of Primary Immunodeficiencies (2012–2017)","datePublished":"2020-12-08T15:33:48Z","dateModified":"2020-12-08T16:21:51+01:00","author":{"@type":"Person","name":"Sabine M. El-Helou"},"publisher":{"@type":"Organization","name":"Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com","logo":{"@type":"ImageObject","url":"https://raphiniert.com/img/raphiniert.png"}},"description":"Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1 to 25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients had (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0 - 88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, only severe combined immunodeficiency (SCID) had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49 % of all patients received immunoglobulin G (IgG) substitution (70% - subcutaneous; 29% - intravenous; 1% - unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment."}</script><script src=https://cdnjs.cloudflare.com/ajax/libs/cookieconsent2/3.1.1/cookieconsent.min.js integrity="sha256-5VhCqFam2Cn+yjw61zbBNrbHVJ6SRydPeKopYlngbiQ=" crossorigin=anonymous></script><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/cookieconsent2/3.1.1/cookieconsent.min.css integrity="sha256-zQ0LblD/Af8vOppw18+2anxsuaz3pWYyVWi+bTvTH8Q=" crossorigin=anonymous><script>window.addEventListener("load",function(){window.cookieconsent.initialise({"palette":{"popup":{"background":"#d9230f","text":"#fff"},"button":{"background":"#fff","text":"#d9230f"}},"theme":"classic","content":{"message":"This website uses cookies to ensure you get the best experience on our website.","dismiss":"Got it!","link":"Learn more","href":"/privacy/"}})});</script><meta name=google-site-verification content=5FMa7RYkPr6QEWWr1ERvyTkIv5k9JmamL7oeGWeGo9Q><script type=text/javascript>var _paq=window._paq||[];_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);(function(){var u="//analytics.raphiniert.com/";_paq.push(['setTrackerUrl',u+'schniedel.php']);_paq.push(['setSiteId','2']);var d=document,g=d.createElement('script'),s=d.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.defer=true;g.src=u+'wutz/';s.parentNode.insertBefore(g,s);})();</script><noscript><p><img src="https://analytics.raphiniert.com/schniedel.php?idsite=2&amp;rec=1" style=border:0 alt></p></noscript><title>The German National Registry of Primary Immunodeficiencies (2012–2017) | Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents><aside class=search-results id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Search</h1></div><div class="col-6 col-search-close"><a class=js-search href=#><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Search... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=/><img src=/img/raphiniert.png alt="Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"></a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar aria-expanded=false aria-label="Toggle navigation">
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=/><img src=/img/raphiniert.png alt="Raphael Scheible | Follower of Jesus Christ | Computer Scientist | Researcher - Raphiniert.com"></a></div><div class="navbar-collapse main-menu-item collapse justify-content-center" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=/#about><span>Home</span></a></li><li class=nav-item><a class=nav-link href=/#projects><span>Projects</span></a></li><li class=nav-item><a class=nav-link href=/#publications><span>Publications</span></a></li><li class=nav-item><a class=nav-link href=/jesus><span>Spiritual Life</span></a></li><li class=nav-item><a class=nav-link href=/#contact><span>Contact</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class=nav-item><a class="nav-link js-search" href=#><i class="fas fa-search" aria-hidden=true></i></a></li></ul></div></nav><div class=pub><div class="article-container pt-3"><h1>The German National Registry of Primary Immunodeficiencies (2012–2017)</h1><div class=article-metadata><div><span>Sabine M. El-Helou</span>, <span>Anika-Kerstin Biegner</span>, <span>Sebastian Bode</span>, <span>Stephan R. Ehl</span>, <span>Maximilian Heeg</span>, <span>Maria E. Maccari</span>, <span>Henrike Ritterbusch</span>, <span>Carsten Speckmann</span>, <span>Stephan Rusch</span>, <span>Raphael Scheible</span>, <span>Klaus Warnatz</span>, <span>Faranaz Atschekzei</span>, <span>Renata Beider</span>, <span>Diana Ernst</span>, <span>Stev Gerschmann</span>, <span>Alexandra Jablonka</span>, <span>Gudrun Mielke</span>, <span>Reinhold E. Schmidt</span>, <span>Gesine Schürmann</span>, <span>Georgios Sogkas</span>, <span>Ulrich H. Baumann</span>, <span>Christian Klemann</span>, <span>Dorothee Viemann</span>, <span>Horst von Bernuth</span>, <span>Renate Krüger</span>, <span>Leif G. Hanitsch</span>, <span>Carmen M. Scheibenbogen</span>, <span>Kirsten Wittke</span>, <span>Michael H. Albert</span>, <span>Anna Eichinger</span>, <span>Fabian Hauck</span>, <span>Christoph Klein</span>, <span>Anita Rack-Hoch</span>, <span>Franz M. Sollinger</span>, <span>Anne Avila</span>, <span>Michael Borte</span>, <span>Stephan Borte</span>, <span>Maria Fasshauer</span>, <span>Anja Hauenherm</span>, <span>Nils Kellner</span>, <span>Anna H. Müller</span>, <span>Anett Ülzen</span>, <span>Peter Bader</span>, <span>Shahrzad Bakhtiar</span>, <span>Jae-Yun Lee</span>, <span>Ursula Heß</span>, <span>Ralf Schubert</span>, <span>Sandra Wölke</span>, <span>Stefan Zielen</span>, <span>Sujal Ghosh</span>, <span>Hans-Juergen Laws</span>, <span>Jennifer Neubert</span>, <span>Prasad T. Oommen</span>, <span>Manfred Hönig</span>, <span>Ansgar Schulz</span>, <span>Sandra Steinmann</span>, <span>Klaus Schwarz</span>, <span>Gregor Dückers</span>, <span>Beate Lamers</span>, <span>Vanessa Langemeyer</span>, <span>Tim Niehues</span>, <span>Sonu Shai</span>, <span>Dagmar Graf</span>, <span>Carmen Müglich</span>, <span>Marc T. Schmalzing</span>, <span>Eva C. Schwaneck</span>, <span>Hans-Peter Tony</span>, <span>Johannes Dirks</span>, <span>Gabriele Haase</span>, <span>Johannes G. Liese</span>, <span>Henner Morbach</span>, <span>Dirk Foell</span>, <span>Antje Hellige</span>, <span>Helmut Wittkowski</span>, <span>Katja Masjosthusmann</span>, <span>Michael Mohr</span>, <span>Linda Geberzahn</span>, <span>Christian M. Hedrich</span>, <span>Christiane Müller</span>, <span>Angela Rösen-Wolff</span>, <span>Joachim Roesler</span>, <span>Antje Zimmermann</span>, <span>Uta Behrends</span>, <span>Nikolaus Rieber</span>, <span>Uwe Schauer</span>, <span>Rupert Handgretinger</span>, <span>Ursula Holzer</span>, <span>Jörg Henes</span>, <span>Lothar Kanz</span>, <span>Christoph Boesecke</span>, <span>Jürgen K. Rockstroh</span>, <span>Carolynne Schwarze-Zander</span>, <span>Jan-Christian Wasmuth</span>, <span>Dagmar Dilloo</span>, <span>Brigitte Hülsmann</span>, <span>Stefan Schönberger</span>, <span>Stefan Schreiber</span>, <span>Rainald Zeuner</span>, <span>Tobias Ankermann</span>, <span>Philipp von Bismarck</span>, <span>Hans-Iko Huppertz</span>, <span>Petra Kaiser-Labusch</span>, <span>Johann Greil</span>, <span>Donate Jakoby</span>, <span>Andreas E. Kulozik</span>, <span>Markus Metzler</span>, <span>Nora Naumann-Bartsch</span>, <span>Bettina Sobik</span>, <span>Norbert Graf</span>, <span>Sabine Heine</span>, <span>Robin Kobbe</span>, <span>Kai Lehmberg</span>, <span>Ingo Müller</span>, <span>Friedrich Herrmann</span>, <span>Gerd Horneff</span>, <span>Ariane Klein</span>, <span>Joachim Peitz</span>, <span>Nadine Schmidt</span>, <span>Stefan Bielack</span>, <span>Ute Groß-Wieltsch</span>, <span>Carl F. Classen</span>, <span>Jessica Klasen</span>, <span>Peter Deutz</span>, <span>Dirk Kamitz</span>, <span>Lisa Lassay</span>, <span>Klaus Tenbrock</span>, <span>Norbert Wagner</span>, <span>Benedikt Bernbeck</span>, <span>Bastian Brummel</span>, <span>Eusebia Lara-Villacanas</span>, <span>Esther Münstermann</span>, <span>Dominik T. Schneider</span>, <span>Nadine Tietsch</span>, <span>Marco Westkemper</span>, <span>Michael Weiß</span>, <span>Christof Kramm</span>, <span>Ingrid Kühnle</span>, <span>Silke Kullmann</span>, <span>Hermann Girschick</span>, <span>Christof Specker</span>, <span>Elisabeth Vinnemeier-Laubenthal</span>, <span>Henriette Haenicke</span>, <span>Claudia Schulz</span>, <span>Lothar Schweigerer</span>, <span>Thomas G. Müller</span>, <span>Martina Stiefel</span>, <span>Bernd H. Belohradsky</span>, <span>Veronika Soetedjo</span>, <span>Gerhard Kindle</span>, <span>Bodo Grimbacher</span></div><span class=article-date>January 2019</span></div><div class="btn-links mb-3"><a class="btn btn-outline-primary my-1 mr-1" href=https://www.frontiersin.org/articles/10.3389/fimmu.2019.01272/full target=_blank rel=noopener>PDF</a>
<button type=button class="btn btn-outline-primary my-1 mr-1 js-cite-modal" data-filename=/publication/el-helou-german-2019/cite.bib>
Cite</button>
<a class="btn btn-outline-primary my-1 mr-1" href=https://doi.org/10.3389/fimmu.2019.01272 target=_blank rel=noopener>DOI</a></div></div><div class=article-container><h3>Abstract</h3><p class=pub-abstract>Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1 to 25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients had (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0 - 88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, only severe combined immunodeficiency (SCID) had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49 % of all patients received immunoglobulin G (IgG) substitution (70% - subcutaneous; 29% - intravenous; 1% - unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Type</div><div class="col-12 col-md-9"><a href=/publication/#2>Journal article</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publication</div><div class="col-12 col-md-9"><em>Frontiers in Immunology</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style></div><div class=article-tags><a class="badge badge-light" href=/tags/primary-immunodeficiency-pid/>&#34;Primary immunodeficiency (PID)&#34;</a>
<a class="badge badge-light" href=/tags/clinical-online-database/>&#34;clinical online database&#34;</a>
<a class="badge badge-light" href=/tags/cvid/>&#34;CVID&#34;</a>
<a class="badge badge-light" href=/tags/esid/>&#34;ESID&#34;</a>
<a class="badge badge-light" href=/tags/european-society-for-immunodeficiencies/>&#34;European Society for Immunodeficiencies&#34;</a>
<a class="badge badge-light" href=/tags/gene-therapy-in-pid/>&#34;gene therapy in PID&#34;</a>
<a class="badge badge-light" href=/tags/german-pid-net-registry/>&#34;German PID-NET registry&#34;</a>
<a class="badge badge-light" href=/tags/hsct-hematopoietic-stem-cell-transplant/>&#34;HSCT = hematopoietic stem cell transplant&#34;</a>
<a class="badge badge-light" href=/tags/hsct-in-pid/>&#34;HSCT in PID&#34;</a>
<a class="badge badge-light" href=/tags/igg-substitution-therapy/>&#34;IgG substitution therapy&#34;</a>
<a class="badge badge-light" href=/tags/immune-system/>&#34;Immune System&#34;</a>
<a class="badge badge-light" href=/tags/pid-prevalence/>&#34;PID prevalence&#34;</a>
<a class="badge badge-light" href=/tags/prevalance/>&#34;Prevalance&#34;</a>
<a class="badge badge-light" href=/tags/registry-for-primary-immunodeficiency/>&#34;registry for primary immunodeficiency&#34;</a></div><div class=share-box aria-hidden=true><ul class=share><li><a href="https://twitter.com/intent/tweet?url=https://raphiniert.com/publication/el-helou-german-2019/&amp;text=The%20German%20National%20Registry%20of%20Primary%20Immunodeficiencies%20%282012%e2%80%932017%29" target=_blank rel=noopener class=share-btn-twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https://raphiniert.com/publication/el-helou-german-2019/&amp;t=The%20German%20National%20Registry%20of%20Primary%20Immunodeficiencies%20%282012%e2%80%932017%29" target=_blank rel=noopener class=share-btn-facebook><i class="fab fa-facebook"></i></a></li><li><a href="mailto:?subject=The%20German%20National%20Registry%20of%20Primary%20Immunodeficiencies%20%282012%e2%80%932017%29&amp;body=https://raphiniert.com/publication/el-helou-german-2019/" target=_blank rel=noopener class=share-btn-email><i class="fas fa-envelope"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https://raphiniert.com/publication/el-helou-german-2019/&amp;title=The%20German%20National%20Registry%20of%20Primary%20Immunodeficiencies%20%282012%e2%80%932017%29" target=_blank rel=noopener class=share-btn-linkedin><i class="fab fa-linkedin-in"></i></a></li><li><a href="https://web.whatsapp.com/send?text=The%20German%20National%20Registry%20of%20Primary%20Immunodeficiencies%20%282012%e2%80%932017%29%20https://raphiniert.com/publication/el-helou-german-2019/" target=_blank rel=noopener class=share-btn-whatsapp><i class="fab fa-whatsapp"></i></a></li><li><a href="https://service.weibo.com/share/share.php?url=https://raphiniert.com/publication/el-helou-german-2019/&amp;title=The%20German%20National%20Registry%20of%20Primary%20Immunodeficiencies%20%282012%e2%80%932017%29" target=_blank rel=noopener class=share-btn-weibo><i class="fab fa-weibo"></i></a></li></ul></div><div class="article-widget content-widget-hr"><h3>Related</h3><ul><li><a href=/publication/seidel-european-2019/>The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity</a></li></ul></div></div></div><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/highlight.min.js integrity="sha256-1zu+3BnLYV9LdiY85uXMzii3bdrkelyp37e0ZyTAQh0=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/languages/r.min.js></script><script src=https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin=anonymous></script><script>const code_highlighting=true;</script><script>const search_config={"indexURI":"/index.json","minLength":1,"threshold":0.3};const i18n={"no_results":"No results found","placeholder":"Search...","results":"results found"};const content_type={'post':"Posts",'project':"Projects",'publication':"Publications",'talk':"Talks"};</script><script id=search-hit-fuse-template type=text/x-template>
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script><script src=https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin=anonymous></script><script src=/js/academic.min.600a2e440c16093e23e26e90951c4d4b.js></script><div class=container><footer class=site-footer><p class=powered-by><a href=/privacy/>Datenschutzerklärung</a>
&middot;
<a href=/terms/>Impressum</a></p><p class=powered-by>&copy; 2023 Raphael Scheible
<span class=float-right aria-hidden=true><a href=# class=back-to-top><span class=button_icon><i class="fas fa-chevron-up fa-2x"></i></span></a></span></p></footer></div><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Cite</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&times;</span></button></div><div class=modal-body><pre><code class="tex hljs"></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i>Copy</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i>Download</a><div id=modal-error></div></div></div></div></div></body></html>